Genmab A/S (OTCMKTS:GNMSF) Trading Down 4.9% - Here's What Happened

Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s share price fell 4.9% during mid-day trading on Wednesday . The company traded as low as $211.50 and last traded at $211.50. 5 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 2,708 shares. The stock had previously closed at $222.51.

Genmab A/S Price Performance

The stock has a market cap of $13.97 billion, a price-to-earnings ratio of 12.00 and a beta of 0.92. The firm's 50-day moving average is $204.16 and its 200 day moving average is $206.10.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $3.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.88 by $1.17. Genmab A/S had a net margin of 35.11% and a return on equity of 19.23%. The company had revenue of $765.14 million during the quarter, compared to the consensus estimate of $761.09 million.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.